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Abstract
Background: Many acute and chronic neurological sequelae from the quinoline derivative antimalarial drug
mefloquine, including dizziness and effects on the visual system such as diplopia and blurred vision, may be
attributable to focal central nervous system toxicity. Maculopathy has also been reported with use of mefloquine,
although the mechanism of this effect has remained unclear. Identification of a common mechanism of toxicity
plausibly underlying these visual and non-visual effects may provide broader insights into the acute and chronic
neuropsychiatric effects of this and other quinoline antimalarial drugs.
Case presentation: This case report describes a 30-year-old man of Pakistani descent with sudden onset of
dizziness and diplopia following the administration of mefloquine who developed macular changes diagnosed
as acute central serous chorioretinopathy by angiography and optical coherence tomography. Similarities
between the visual conditions observed in this case and those observed following administration of related
quinoline derivative antimalarial drugs including quinine are considered, and plausible mechanisms for the
observed drug-induced toxicity are discussed.
Conclusions: It is proposed that central serous chorioretinopathy be considered a potential ophthalmological
sign of mefloquine central nervous system toxicity, and for this effect to potentially indicate susceptibility
to other neuropsychiatric effects of mefloquine intoxication. Treating physicians should be aware of the
potential for acute and chronic ocular effects resulting from administration of mefloquine and other quinoline
antimalarial drugs.
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Background
Mefloquine is a quinoline derivative antimalarial drug
structurally related to quinine that has been previously
widely used in the treatment and prophylaxis of malaria.
Recently its popularity has declined as awareness has
grown of the drug’s focal central nervous system (CNS)
toxicity, which is associated with a wide range of acute
and chronic neurological sequelae including vertigo, loss
of balance, and symptoms of polyneuropathy which may
be irreversible [1], as well as certain neuropsychiatric
effects including cognitive impairment which may last
years after use [2]. Although not widely recognized in
the literature [3, 4], certain visual effects associated
with mefloquine use including blurred vision or accom-
modative dysfunction may also be plausibly attributable
to focal CNS toxicity [1, 5].
While dizziness [1], diplopia [6], and maculopathy [7]
have been previously reported separately with mefloquine
use, these conditions have not previously been reported
together, and confirmation of central serous chorioretino-
pathy (CSCR) has not been previously reported. Identifica-
tion of a common mechanism of CNS toxicity plausibly
underlying both these visual and non-visual effects would
have implications for better understanding of the acute
and chronic neuropsychiatric effects of intoxication with
mefloquine and other quinoline antimalarial drugs.
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We present a case of these adverse events occurring
together in a man treated with mefloquine for presumed
malaria, and propose the novel theory that CSCR may
represent an ophthalmological sign of mefloquine CNS
toxicity.
Case presentation
A 30-year-old man of Pakistani descent was referred to
ophthalmology with a history of sudden profound dim-
inution of vision in his right eye 3 days earlier associated
with transient diplopia and dizziness. He had a recent his-
tory of febrile illness marked by constitutional symptoms
including headache and myalgia 20 days earlier when he
traveled to his native country. Although no peripheral
blood smears or rapid diagnostic testing were obtained,
on suspicion of malaria, he was immediately treated by
a local physician with 2500 mg of chloroquine over 3 days,
followed by 15 mg of primaquine daily over 14 days, and
then with 1500 mg of mefloquine in three divided doses
over 24 hours. Apart from symptoms related to his initial
febrile illness, he was asymptomatic until he received mef-
loquine. Its introduction was associated with an onset of
diplopia, blurred vision in his right eye, dizziness, nausea,
and vomiting after intake of the first dose, with blurred
vision progressing over the course of dosing. These symp-
toms prompted the temporary addition of omeprazole
and domperidone, and the combination chlordiazepoxide-
clidinium bromide, the latter of which was discontinued
the day prior to presentation to ophthalmology, by which
time all symptoms had resolved but the progressive
blurred vision.
There was no history of observed nystagmus nor was
there a history of obvious psychiatric symptoms. He
smoked tobacco occasionally but did not consume alco-
hol or recreational drugs. He denied prior use of steroid
drugs.
On examination 4 days after the onset of visual symp-
toms, his uncorrected visual acuity for his right eye
(OD; oculus dexter) was 20/100 at distance and 20/50
at near, and for his left eye (OS; oculus sinister) his un-
corrected visual acuity was 20/20 near and distance.
His best-corrected visual acuity was unchanged with a
manifest refraction of +1.5 diopters (D) sphere OD and
+0.25 D sphere OS. Extraocular muscles were unrestricted
in both eyes and the cover test demonstrated orthophoria.
There was no diplopia. His right eye anterior segment was
quiet and had no evidence of cornea verticillata. There
was no relative afferent pupillary defect or anisocoria. The
intraocular pressure was 18 mm Hg in both eyes. An
Amsler grid suggested a large area of central metamor-
phopsia in his right eye and, corresponding to this, a
fundus examination revealed a large ovoid area of dome-
shaped serous elevation of retina between the temporal
arcades of the retina in his right eye, including the entire
macula and reaching close to the temporal border of the
disc (Fig. 1). His left eye was normal. His color vision as
tested on Ishihara’s tests (38 plates) was normal. Optic
coherence tomography (OCT) revealed serous elevation
of his right eye neurosensory retina (Fig. 2). Fluorescein
angiography revealed focal leaks of the retinal pigment
epithelium within one disc diameter superotemporal to
the disc that appeared hyperfluorescent in the arterial
phase. One of them acquired an ink blot appearance in
the late phase (Fig. 3). A diagnosis of unilateral CSCR
was made, and he was referred to an internist for further
evaluation. His vital signs were normal, and neurological,
musculoskeletal, and psychiatric evaluations were noncon-
tributory, although a detailed neuropsychiatric evaluation
was not performed. He was asked to discontinue all
medicines. His visual acuity steadily improved and the
neurosensory retinal elevation receded. Eleven weeks
after presentation, he had an uncorrected visual acuity
of 20/20 distance and near in both eyes with no abnor-
mality on OCT.
Six months later, he reported visual disturbance in his
right eye but a clinical examination and OCT ruled out
recurrence. However, 1 year after his initial presentation,
he reported mild blurring in his right eye. His best-
corrected visual acuity was 20/25 distance and 20/20
near, and a leak similar in location to the primary one
was noted and treated with focal laser photocoagulation.
His visual acuity returned to baseline after 7 weeks. When
last seen, 44 months after the initial episode, his visual
acuity was stable at 20/20 near and distance in both eyes,
Fig. 1 Fundus with site of leak (black arrow) showing gross elevation
of neurosensory retina (white arrows) that includes the entire macula
and reaches close to the temporal border of the disc
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and a scar was visible between the macula and the disc
representing the area that had focal laser treatment (Fig. 4).
Discussion
Based on our review of the literature, to the best of our
knowledge this is the first report of a confirmed case of
unilateral CSCR associated with use of mefloquine. With
the exception of our patient’s residual focal scarring, which
represents the effects of overly strong focal laser, our pa-
tient fortunately made an unremarkable recovery without
other chronic sequelae.
Walker and Colleaux suspected a possible bilateral
CSCR or inflammatory insult in an asymptomatic patient
with macular changes incidentally discovered following
from a large cumulative dose (19.5 g) of mefloquine con-
sumed over a year and a half [7]. In contrast, in our pa-
tient, CSCR was confirmed in association with transient
dizziness and diplopia that developed following acute
exposure to the drug.
We consider it unlikely in our case that drugs other
than mefloquine could have primarily induced the CSCR
and accompanying symptoms. Our patient emphasized
that the onset of blurred vision and diplopia occurred
within hours of his intake of mefloquine and prior to his
use of other drugs used to later manage dizziness and
vomiting. He also emphasized that none of these symptoms
were observed during administration of earlier antimalarial
drugs alone. Although causal attribution to mefloquine is
plausible in this case based both on the timing of symptom
onset and the drug’s prior reported association with dizzi-
ness and diplopia, the underlying mechanism of the CSCR
may be less readily apparent.
One possible mechanism for the CSCR could be a direct
effect of mefloquine on the retina. Mefloquine and related
quinoline antimalarial drugs are potent blockers of con-
nexins, including connexin43 [8], which are expressed
throughout the epithelium, glia, and Müller cells, as
well as the retinal and choroidal circulation [9] where
they serve to facilitate intercellular electrical and meta-
bolic communication through their apposition at cell
membranes in hexameric structures known as gap junc-
tions [10]. In this case, it is plausible that connexin43
gap junction blockade at the level of the choroidal vascu-
lature and retinal pigment epithelium could have resulted
in increased choroidal vascular permeability and extrava-
sation of fluid underneath the retinal pigment epithelium.
For example, gap junction dysfunction in congenital ocu-
lodentodigital dysplasia arising from an autosomal domin-
ant mutation of the gap junction protein alpha-1 (GJA1)
gene coding for connexin43 results in iridociliary cysts,
thought to be due to abnormal adhesion of epithelial cells
[11]. However, arguing against this possibility in our case
is that there were no anterior segment sequelae, implying
the absence of similar disruptions elsewhere despite the
extensive expression of connexin43 throughout his eye. In
addition, such a mechanism does not readily explain the
reported dizziness or diplopia, and neither does it explain
Fig. 2 Optical coherence tomography showing the elevation of
neurosensory retina, more marked nasally; the central foveal
thickness is 453 μm, while the maximum thickness is 794 μm
Fig. 3 Fluorescein angiography revealing a focal leak that progressed
to an ink blot appearance in the late phase
Fig. 4 Macular changes 44 months after presentation
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the unilateral nature of the observed CSCR. In contrast,
recent insights into the toxic effects of mefloquine on the
CNS [1] may provide an alternative and more plausible
explanation for these visual and non-visual effects.
Serous elevation in CSCR is characterized by detach-
ment of the neurosensory retina due to focal leakage of
choroidal interstitial fluid. Recent improvements in angi-
ography now suggest that CSCR arises when increased
hydrostatic pressure in the choroid associated with chor-
oidal hyperpermeability reverses the normal physiologic
flow of fluid from the retina to the choroid [12]. This
hyperpermeability may arise with transient capillary and
venous hyperemia [13], such as may occur from loss of
opposition to sympathetics from decreased parasympa-
thetic tone. Sympathomimetic agents have been associ-
ated in the literature with cases of CSCR [14], including
unilateral CSCR [15].
Given this pathophysiology, we argue that it is plausible
that the unilateral CSCR in this case could be attributable
to a transient loss of parasympathetic innervation to the
ipsilateral ciliary ganglion (CG), leading to alterations in
choroidal blood flow. Direct focal effects on either the
ipsilateral parasympathetic preganglionic neurons in the
Edinger–Westphal nucleus (EWN) [16], which relay in
the CG to postganglionic neurons innervating both the
iris and smooth muscle regulating choroid blood flow
[17, 18], or on afferents in the hypothalamus supply-
ing the EWN, including the suprachiasmatic nucleus
(SCN) [18], could conceivably cause these effects.
Mefloquine has been previously shown to directly affect
electrical activity in the hypothalamus [19], and histo-
pathologically confirmed focal neurotoxic lesions within
the hypothalamus [20, 21] and in the vicinity of the EWN
[22] have been previously reported with related quinoline
derivative antimalarial drugs.
Other symptoms consistent with loss of CG parasym-
pathetic innervation, including loss of accommodation
and mydriasis [23] responsive to local pilocarpine [24],
phenylephrine [25], or to stellate ganglion block [25] and
associated with sudden visual disturbance, including
unilateral blindness [26], have been previously reported
from the related quinoline antimalarial quinine.
Consistent with other confirmed focal CNS effects of
mefloquine, including on the brainstem vestibular [27],
gracilis, and cuneatus nuclei [28], a reversible transient
effect of mefloquine on the functioning either of the
ipsilateral EWN, or upstream on hypothalamic centers,
would provide a highly parsimonious explanation for
the observed unilateral CSCR. In this case, the persist-
ent visual disturbance following resolution of acute
symptoms may be considered secondary to the result-
ant serous elevation of the neurosensory retina causing
retinal dysfunction, which would resolve only over a
prolonged period.
Correspondingly, a reversible transient effect on adjacent
oculogyric centers might similarly explain our patient’s
reported brief diplopia, while a similar transient effect
on adjacent vestibulo-oculomotor centers might explain
his brief dizziness [27]. Transient blurring of vision with
mefloquine, consistent with a reversible anomalous ac-
commodation, has been previously reported [29], and is a
feature of idiosyncratic quinoline toxicity, including from
quinine [30] and from numerous experimental quinoline
antimalarial drugs [31–33]. Lack of observed pupillary
abnormality and diplopia at our patient’s initial presen-
tation would be consistent with such transient effects
resolving early.
With regard to the plausible effect of other drugs, either
a retinal or CNS mechanism could provide for the con-
comitant drugs reported in this case contributing to a
complex synergistic toxicity. Both chloroquine and prima-
quine would be expected to modulate the P-glycoprotein
(P-gp)-mediated efflux of mefloquine [34], either within
the retinal pigment epithelium or within the CNS, poten-
tially contributing to its abnormal accumulation. Similarly,
domperidone [35], chlordiazepoxide [36], and omeprazole
[37] are known substrates of P-gp, and any of these drugs
may have further exacerbated mefloquine’s effects by com-
peting for available drug transport sites in the blood–
retinal or blood–brain barriers.
Conclusions
In this case, principally on the basis of parsimony, we pos-
tulate that mefloquine — either alone or in synergy with
other P-gp substrates or quinoline antimalarial drugs —
caused dizziness, diplopia, and CSCR through transient
focal effects on specific structures of our patient’s CNS.
This case raises questions as to the possible existence of a
CNS class effect among closely related quinoline antimal-
arial drugs including quinine, which have been previously
associated with similar transient unilateral blindness and
blurring of vision.
We propose that CSCR should therefore be considered
a potential sign of mefloquine intoxication [1] and more
generally of quinoline CNS toxicity, and should prompt
a careful clinical evaluation for other evidence of neuro-
psychiatric toxicity. In our case, insight into a possible CNS
etiology came too late to inform clinical application, but
fortunately our patient appears to have been spared the
chronic cognitive sequelae, including cognitive dysfunction,
which may affect a sizable minority of those reporting
neuropsychiatric adverse effects from the drug [2].
Treating physicians should refrain from using meflo-
quine in patients with a history of CSCR and should be
aware of the potential for acute and chronic ocular effects
resulting from the drug’s administration, particularly in
combination with other P-gp substrates or inhibitors. Dur-
ing prophylactic use, the onset of such effects should be
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considered potential evidence of idiosyncratic suscepti-
bility to mefloquine intoxication, and should prompt
the immediate substitution of the drug for an alterna-
tive non-quinoline antimalarial.
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